| 000 | 01595 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513134119.0 | ||
| 264 | 0 | _c19980226 | |
| 008 | 199802s 0 0 eng d | ||
| 022 | _a0300-9564 | ||
| 024 | 7 |
_a10.1007/BF01285556 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGasparini, M | |
| 245 | 0 | 0 |
_aCognitive improvement during Tolcapone treatment in Parkinson's disease. _h[electronic resource] |
| 260 |
_bJournal of neural transmission (Vienna, Austria : 1996) _c1997 |
||
| 300 |
_a887-94 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAttention _xdrug effects |
| 650 | 0 | 4 |
_aBenzophenones _xtherapeutic use |
| 650 | 0 | 4 | _aCatechol O-Methyltransferase Inhibitors |
| 650 | 0 | 4 |
_aCognition _xdrug effects |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMemory _xdrug effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 | _aNeuropsychological Tests |
| 650 | 0 | 4 | _aNitrophenols |
| 650 | 0 | 4 |
_aNorepinephrine _xmetabolism |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aTolcapone |
| 700 | 1 | _aFabrizio, E | |
| 700 | 1 | _aBonifati, V | |
| 700 | 1 | _aMeco, G | |
| 773 | 0 |
_tJournal of neural transmission (Vienna, Austria : 1996) _gvol. 104 _gno. 8-9 _gp. 887-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF01285556 _zAvailable from publisher's website |
| 999 |
_c9420828 _d9420828 |
||